Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Seven research teams across the U.S. to develop new drugs for nervous system disorders

The National Institutes of Health has made awards to investigators across the United States for an ambitious set of projects seeking to develop new drugs for disorders of the nervous system.

19 Aug 2011

NIH/NINDS awards AMRI to develop pre-clinical drug candidate for spinal muscular atrophy

AMRI today announced it received a federal contract award from the National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) to provide chemistry and other drug discovery technologies in support of NINDS' Medicinal Chemistry for Neurotherapeutics Program (MCNP), part of the NIH Blueprint Neurotherapeutics Network.

19 Aug 2011

Lucentis receives Health Canada approval for treatment of retinal vein occlusion

Following a priority review, Health Canada has approved Lucentis (ranibizumab) as a treatment for vision loss resulting from retinal vein occlusion (RVO). This makes Lucentis the first approved treatment of its class in Canada for this debilitating condition. Patients will now have access to a treatment that is proven to be effective and has an established safety profile.

18 Aug 2011

La Jolla Institute's new RNAi Center to focus on genetics behind myriad diseases

A major Center that will propel scientific efforts to pinpoint the specific genes involved in causing immune diseases, cancer and other diseases will be opened today at the La Jolla Institute for Allergy & Immunology.

12 Aug 2011

Single engineered protein blocks two related angiogenic receptors

Cancer needs blood. In fact, some cancer medications work solely to slow or prevent cancer cells from creating new capillaries, choking off their much-needed blood and nutrient supply to halt the growth of tumors.

12 Aug 2011

Researchers team up to combat age-related macular degeneration

A professor at the University of California, Riverside Bourns College of Engineering has received a $100,000 grant to develop a new technique to fight a disease that gradually destroys vision.

8 Aug 2011

Early detection critical in preventing vision loss among Baby Boomers

Probably the most worrisome health concern for Baby Boomers as they age is the increased possibility of visual impairment or vision loss. For this reason, early detection is critical in successfully preventing and treating eye conditions such as macular degeneration, cataracts, glaucoma and diabetic retinopathy, before they lead to major visual changes.

27 Jul 2011

New convenient device can track degenerative eye disease

An ophthalmologist at UT Southwestern Medical Center has helped create a convenient device that lets patients who have a degenerative eye disease better track vision changes.

27 Jul 2011

Inotek completes two stages of INO-8875 Phase 2b trial against glaucoma

Inotek Pharmaceuticals Corp., a leader in the development of innovative medicines to address significant diseases of the eye, today announced that the Company has successfully completed the first two of three stages of a multiple-dose Phase 2b clinical trial of its novel eye-drop candidate, INO-8875, in patients with glaucoma or ocular hypertension.

22 Jul 2011

Study: Overall awareness about eye health lower among ethnic Americans

The results of recent, comprehensive research supported by Transitions Optical revealed that the majority of Americans are not taking the proper steps to care for the health of their eyes, and that awareness of both short- and long-term effects of UV exposure on vision is remarkably low.

15 Jul 2011

Novel bionic eyes for the blind in the making

British scientists have developed the first pair of bionic glasses that could help thousands of legally blind people. These glasses using tiny cameras and software technology from video games, alert the wearer to objects in their surroundings using flashing lights.

14 Jul 2011

Positive results from sarilumab Phase 2b trial on RA, ankylosing spondylitis

Sanofi and Regeneron Pharmaceuticals, Inc. announced results from Phase 2b trials in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) with sarilumab, a novel, high-affinity, subcutaneously administered, fully-human antibody targeting the interleukin-6 receptor.

13 Jul 2011

AHAF awards 22 new grants to scientists worldwide for innovative vision research

The American Health Assistance Foundation (AHAF), a nonprofit organization with a history of funding cutting-edge research on age-related diseases, announced today that it has awarded 22 new grants totaling nearly $2.2 million to scientists worldwide who are studying glaucoma and macular degeneration. The two conditions are the leading causes of irreversible vision loss and blindness in the U.S.

8 Jul 2011

Healthy diet might help reduce risk of macular degeneration

Eating a diet high in vitamin D, as well as the nutrients betaine and methionine, might help reduce the risk of macular degeneration, according to new research conducted by Tufts Medical Center scientists. Their study of identical twins from the US World War II Twin Registry also found that the more a person smoked, the higher their risk of developing macular degeneration.

6 Jul 2011

Checklist to stay healthy and active in summer

The summer is a great season for getting in shape. Whether by playing a sport, doing an aerobic exercise routine, or just returning to that familiar running path -- this is the time for activity.

2 Jul 2011

Positive results from RISE and RIDE Phase III trials of Genentech's Lucentis for diabetic macular edema

Genentech, a member of the Roche Group, today announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the efficacy and safety of Lucentis (ranibizumab injection) in people with diabetic macular edema (DME).

29 Jun 2011

Bayer Yakuhin seeks marketing authorization in Japan for EYLEA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application to the Ministry of Health, Labor and Welfare (MHLW) in Japan for marketing authorization for EYLEA, also known as VEGF Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration (wet AMD).

29 Jun 2011

Flamel, Digna Biotech enter joint development agreement for multiple products

Flamel Technologies SA and Digna Biotech SL today announced that the two companies have entered into a joint development agreement for the pre-clinical and clinical development of multiple products.

27 Jun 2011

Adeona enters agreement to begin proprietary zinc-based therapy Phase IIb trial in ALS

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has expanded its pipeline of proprietary zinc-based therapies to include a planned Phase IIb clinical trial of patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.

24 Jun 2011

Oxford BioMedica reports RetinoStat progress in Phase I study against wet AMD

Oxford BioMedica plc, a leading gene therapy company, today announces that the first dose level of RetinoStat is safe and well-tolerated at one month following treatment.

22 Jun 2011

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Seven research teams across the U.S. to develop new drugs for nervous system disorders

NIH/NINDS awards AMRI to develop pre-clinical drug candidate for spinal muscular atrophy

Lucentis receives Health Canada approval for treatment of retinal vein occlusion

La Jolla Institute's new RNAi Center to focus on genetics behind myriad diseases

Single engineered protein blocks two related angiogenic receptors

Researchers team up to combat age-related macular degeneration

Early detection critical in preventing vision loss among Baby Boomers

New convenient device can track degenerative eye disease

Inotek completes two stages of INO-8875 Phase 2b trial against glaucoma

Study: Overall awareness about eye health lower among ethnic Americans

Novel bionic eyes for the blind in the making

Positive results from sarilumab Phase 2b trial on RA, ankylosing spondylitis

AHAF awards 22 new grants to scientists worldwide for innovative vision research

Healthy diet might help reduce risk of macular degeneration

Checklist to stay healthy and active in summer

Positive results from RISE and RIDE Phase III trials of Genentech's Lucentis for diabetic macular edema

Bayer Yakuhin seeks marketing authorization in Japan for EYLEA for treatment of wet AMD

Flamel, Digna Biotech enter joint development agreement for multiple products

Adeona enters agreement to begin proprietary zinc-based therapy Phase IIb trial in ALS

Oxford BioMedica reports RetinoStat progress in Phase I study against wet AMD

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in